Seeking Alpha

Shares of Cyclacel Pharmaceutical (CYCC -3.9%) slide after releasing updated survival data over...

Shares of Cyclacel Pharmaceutical (CYCC -3.9%) slide after releasing updated survival data over the weekend from its Phase III studies of its oral sapacitabine capsules, a treatement for elderly patients with newly diagnosed acute myeloid leukemia who are not candidates for chemotherapy. The data was presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|